InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.45
(
-1.86%
)
US TECH 100
19,467.60
(
0.59%
)
Dow Jones
41,763.46
(
-0.90%
)
Brent Oil
74.21
(
0.26%
)
Bitcoin
69,994.32
(
-0.30%
)
Post# of 253503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120650
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 59272

Friday, 11/14/2008 5:17:04 PM

Friday, November 14, 2008 5:17:04 PM

Post# of 253503
Teva Challenges US Truvada Patent

[Technically, the challenge is against GILD’s patents on Emtriva, one of the two constituent drugs in Truvada; however, Emtriva is hardly ever used other than as a component in Truvada and hence it makes much more sense for Teva to submit an ANDA for Truvada (as it has done) rather than an ANDA for Emtriva.

The loss of US patent protection for Truvada would be devastating for GILD because Truvada is the leading nucleoside backbone in three-drug HIV cocktails that dominate the early lines of treatment (see data in #msg-32944110 and pie chart in #msg-26915314). Moreover, a loss by GILD in the Truvada patent challenge would put its US Atripla patent at risk.]

http://biz.yahoo.com/bw/081114/20081114005887.html

›Gilead Sciences Announces Notification of ANDA Filing for Truvada

Friday November 14, 4:30 pm ET

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD ) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Truvada® (emtricitabine and tenofovir disoproxil fumarate).

In the Notice Letter, Teva alleges that two of the patents associated with emtricitabine – U.S. Patent Numbers 6,642,245 and 6,703,396 – owned by Emory University and licensed exclusively to Gilead Sciences are invalid, unenforceable and/or will not be infringed by Teva’s manufacture, use or sale of the product described in its ANDA submission.

Gilead is currently reviewing the Notice Letter and has 45 days from the date of receipt to commence a patent infringement lawsuit against Teva. Such a lawsuit would restrict the FDA from approving Teva’s ANDA for up to 30 months or until a district court decision that is adverse to Gilead, whichever occurs first. Truvada is currently protected by 10 patents, which are listed in the FDA’s Approved Drugs Products List, and all 10 patents would need to be invalidated or expired before a generic version of Truvada could be marketed.‹

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up